SAGE — Sage Therapeutics Share Price
0.000.00%
Last trade - 00:00- $457.13m
- $33.28m
- $41.24m
- 31
- 20
- 39
- 19
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.12 | ||
| Price to Tang. Book | 1.12 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 9.64 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -91.01% | ||
| Return on Equity | -63.53% | ||
| Operating Margin | -806.16% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1,114.2 | 6.31 | 7.69 | 86.45 | 41.24 | 80.82 | 138.63 | 43.12% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed two FDA-approved treatments indicated for postpartum depression (PPD) and is advancing a portfolio of internally discovered novel chemical entities with the potential to become differentiated treatments designed to improve brain health by primarily targeting two critical central nervous system, receptor systems, GABA and NMDA. Its product ZURZUVAE is for the treatment of PPD in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, and is the first oral, once-daily, 14-day treatment specifically indicated for adults with PPD. It is also evaluating potential indications for SAGE-324, a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing, including seizures in developmental and epileptic encephalopathies. Its other areas of focus are SAGE-319, SAGE-039, and SAGE-817.
Directors
- Kevin Starr NEC (58)
- Barry Greene PRE (58)
- Kimi Iguchi CFO (58)
- Anne Cook SVP (59)
- Albert Robichaud CSO (60)
- Jeffrey Jonas OTH (68)
- Chris Benecchi OTH
- Stephen Kanes OTH (56)
- Elizabeth Barrett IND (58)
- Michael Cola IND (61)
- James Frates IND (53)
- Geno Germano IND (60)
- George Golumbeski IND (63)
- Steven Paul IND (70)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- April 16th, 2010
- Public Since
- July 18th, 2014
- No. of Shareholders
- 7
- No. of Employees
- 353
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 62,620,694
- Address
- 55 Cambridge Parkway, CAMBRIDGE, 02142
- Web
- https://www.sagerx.com/
- Phone
- +1 6172998380
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for SAGE
SAGE Therapeutics Inc Annual Shareholders Meeting
Q2 2025 SAGE Therapeutics Inc Earnings Release
Q3 2025 SAGE Therapeutics Inc Earnings Release
Similar to SAGE
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Sage Therapeutics share price?
As of Today at 23:02 UTC, shares in Sage Therapeutics are trading at $7.30. This share price information is delayed by 15 minutes.
How has the Sage Therapeutics share price performed this year?
Shares in Sage Therapeutics last closed at $7.30 and the price had moved by -44.3% over the past 365 days. In terms of relative price strength the Sage Therapeutics share price has underperformed the S&P500 Index by -49.77% over the past year.
What are the analyst and broker recommendations for Sage Therapeutics?
The overall consensus recommendation for Sage Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Sage Therapeutics dividend yield?
Sage Therapeutics does not currently pay a dividend.
Does Sage Therapeutics pay a dividend?
Sage Therapeutics does not currently pay a dividend.
When does Sage Therapeutics next pay dividends?
Sage Therapeutics does not currently pay a dividend.
How do I buy Sage Therapeutics shares?
To buy shares in Sage Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Sage Therapeutics?
As of the previous close price of $7.30, shares in Sage Therapeutics had a market capitalisation of $457.13m.
Where are Sage Therapeutics shares listed?
Here are the trading details for Sage Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: SAGE
What kind of share is Sage Therapeutics?
Based on an overall assessment of its quality, value and momentum Sage Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Sage Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Sage Therapeutics is $8.05. That is 10.27% above the last closing price of $7.30.
Analysts covering Sage Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$3.65 for the next financial year.
Find out moreWhat is the trend in the Sage Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sage Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +21.21%.
As of the last closing price of $7.30, shares in Sage Therapeutics were trading -0.12% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Sage Therapeutics PE Ratio?
The Sage Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $7.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Sage Therapeutics?
Sage Therapeutics' management team is headed by:
- Kevin Starr - NEC
- Barry Greene - PRE
- Kimi Iguchi - CFO
- Anne Cook - SVP
- Albert Robichaud - CSO
- Jeffrey Jonas - OTH
- Chris Benecchi - OTH
- Stephen Kanes - OTH
- Elizabeth Barrett - IND
- Michael Cola - IND
- James Frates - IND
- Geno Germano - IND
- George Golumbeski - IND
- Steven Paul - IND